Authors
Beth Fand Incollingo
Latest:
Addition to avelumab to best supportive care after firstline chemo improves OS in advanced urothelial CaAvelumab (Bavencio) as a maintenance treatment after chemotherapy significantly extended overall survival in patients with advanced urothelial cancer, according to findings from thephase III JAVELIN Bladder 100 trial.
Brett Watson, MD
Latest:
Management of UTUC using a kidney-sparing approachAdvances in endourology have made kidney-sparing treatments a viable treatment option.
Jason M. Hafron, MD, CMO
Latest:
Jason Hafron, MD, on PSMA-PET in oligometastatic disease“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.
Joshua Calvert, MD, MPH
Latest:
Robotics in GU oncology: Current status, future directionsThe breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.
